Join to View Full Profile
2200 Ofarrell StSan Francisco, CA 94115
Phone+1 415-833-2000
Dr. Hua is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts General HospitalFellowship, Vascular Surgery - Independent, 2003 - 2005
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Surgery, 1996 - 2003
Keck School of Medicine of the University of Southern CaliforniaClass of 1996
Certifications & Licensure
CA State Medical License 1997 - 2025
MA State Medical License 2003 - 2005
American Board of Surgery Surgery- American Board of Surgery Vascular Surgery
Clinical Trials
- The Vascutek AnacondaTM Stent Graft System Phase II IDE Study Start of enrollment: 2009 Apr 01
- Zenith TX2® Post-market Approval Study Start of enrollment: 2009 Jul 10
- Evaluation of the GORE TIGRIS Vascular Stent Start of enrollment: 2012 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsSurgical management of middle aortic syndrome in an adultHubert Y. Luu, Marisa E. Pulcrano, Hong Ton Hua
Journal of Vascular Surgery Cases and Innovative Techniques. 2020-03-01 - 13 citationsLong-term freedom from aneurysm-related mortality remains favorable after endovascular abdominal aortic aneurysm repair in a 15-year multicenter registry.Nicole Rich, Lue-Yen Tucker, Steven Okuhn, Hong Hua, Bradley B. Hill
Journal of Vascular Surgery. 2017-06-01 - 81 citationsType II endoleak with or without intervention after endovascular aortic aneurysm repair does not change aneurysm-related outcomes despite sac growth.Joy Walker, Lue-Yen Tucker, Philip P. Goodney, Leah Candell, Hong Hua
Journal of Vascular Surgery. 2015-09-01
Press Mentions
Impact of Sequencing Targeted Therapies with High-Dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients with Metastatic Renal Cell Carcinoma from an on-Going Observational IL-2 Clinical Trial: PROCLAIM SMFebruary 1st, 2017
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
